Reis, GilmarSilva, Eduardo Augusto dos Santos MoreiraSilva, Daniela Carla MedeirosThabane, LehanaMilagres, Aline CruzFerreira, Thiago SantiagoSantos, Castilho Vitor Quirino dosCampos, Vitoria H. S.Nogueira, Ana Maria RAlmeida, Ana Paula Figueiredo Guimarães deCallegari, Eduardo DinizFigueiredo Neto, Adhemar Dias deSavassi, Leonardo Cançado MonteiroSimplicio, Maria Izabel CamposRibeiro, Luciene BarraOliveira, RosemaryHarari, OfirForrest, Jamie I.Ruton, HindaSprague, SheilaMckay, PaulaGuo, Christina M.Rowland-Yeo, KantersGuyatt, Gordon HenryBoulware, David R.Rayner, Craig R.Mills, Edward Joseph2023-06-262023-06-262022REIS, G. et al. Effect of early treatment with ivermectin among patients with covid-19. The New England Journal of Medicine, v. 386, n. 18, 2022. Disponível em: <https://www.nejm.org/doi/full/10.1056/nejmoa2115869>. Acesso em: 11 out. 2022.1533-4406.http://www.repositorio.ufop.br/jspui/handle/123456789/16802BACKGROUND The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus dis- ease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coro- navirus 2 (SARS-CoV-2), is unclear. METHODS We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2–positive adults recruited from 12 public health clinics in Brazil. Patients who had had symptoms of Covid-19 for up to 7 days and had at least one risk factor for disease progression were randomly assigned to receive ivermectin (400 μg per kilogram of body weight) once daily for 3 days or placebo. (The trial also involved other interventions that are not reported here.) The primary composite outcome was hospitalization due to Covid-19 within 28 days after randomization or an emergency department visit due to clinical worsening of Covid-19 (defined as the participant remaining under observation for >6 hours) within 28 days after randomization. RESULTS A total of 3515 patients were randomly assigned to receive ivermectin (679 patients), placebo (679), or another intervention (2157). Overall, 100 patients (14.7%) in the ivermectin group had a primary-outcome event, as compared with 111 (16.3%) in the placebo group (relative risk, 0.90; 95% Bayesian credible interval, 0.70 to 1.16). Of the 211 primary-outcome events, 171 (81.0%) were hospital admissions. Find- ings were similar to the primary analysis in a modified intention-to-treat analysis that included only patients who received at least one dose of ivermectin or placebo (relative risk, 0.89; 95% Bayesian credible interval, 0.69 to 1.15) and in a per-protocol analysis that included only patients who reported 100% adherence to the assigned regimen (relative risk, 0.94; 95% Bayesian credible interval, 0.67 to 1.35). There were no significant effects of ivermectin use on secondary outcomes or adverse events. CONCLUSIONS Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. (Funded by FastGrants and the Rainwater Charitable Foundation; TOGETHER ClinicalTrials.gov number, NCT04727424.)en-USrestritoArtigo publicado em periodicohttps://www.nejm.org/doi/full/10.1056/nejmoa2115869https://doi.org/10.1056/NEJMoa2115869